ED Implant denied as experimental or investigational by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for ed implant are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied Your Penile Implant as Experimental — and How to Appeal

An experimental or investigational denial from Blue Cross Blue Shield means BCBS has determined that a penile prosthesis (inflatable or malleable) lacks sufficient evidence to meet its coverage criteria for established, non-experimental treatment. This denial is surprising given the long clinical history of penile implants, but it can occur when BCBS's policy version applies a narrow evidence standard, when a newer implant device model is involved, or when the underlying condition is categorized differently in the claim.

### Why This Denial Is Appealable

Penile prosthesis surgery has decades of peer-reviewed evidence, is included in American Urological Association (AUA) clinical guidelines, and has FDA 510(k) clearance for the devices themselves. An "experimental" classification that ignores this established clinical record is facially inconsistent with the weight of medical evidence and with most state insurance laws requiring coverage of treatments supported by adequate clinical evidence. Under ACA §2719 and most state external review laws, an independent reviewer applying objective clinical standards — not just the plan's internal policy — can overturn this classification.

### Federal Appeal Framework

• Internal appeal: Request the full text of BCBS's experimental/investigational policy and the specific criteria applied. Submit a written internal appeal within the deadline on your denial notice.
• External review (ACA §2719): External review by an Independent Review Organization (IRO) is particularly powerful for experimental denials because the IRO applies an objective, evidence-based standard rather than BCBS's proprietary definition. The window to request external review is approximately four months from denial; verify your exact deadline.
• Expedited review: Available when delay would seriously jeopardize health. Typically decided within 72 hours.
• State insurance department: Fully insured plans are subject to state prompt-payment and coverage mandates; an experimental denial unsupported by the evidence record may also be reviewable as a bad-faith determination.

### What to Gather

1. FDA clearance documentation — the 510(k) clearance number for the specific device; this is publicly available on the FDA's device database. 2. Diagnosis and prior treatment failure — urologist records documenting organic erectile dysfunction, etiology, and exhaustion of conservative therapies. 3. Clinical literature summary — your urologist or a medical literature search can identify relevant peer-reviewed sources supporting implant surgery; do not cite specific statistics in the appeal, but reference the body of published evidence and AUA guideline support. 4. Prescriber medical-necessity letter — stating that the device is FDA-cleared, guideline-supported, and not investigational, and rebutting each specific basis BCBS cited for the experimental determination. 5. BCBS experimental/investigational policy — obtain and copy each criterion into your appeal to demonstrate the device satisfies them.

### Criteria-Mapping Structure

List each element of BCBS's experimental-status definition. For each element, provide a factual response: FDA clearance status, inclusion in named professional society guidelines (AUA), availability as a standard-of-care procedure at major urology centers, and peer-reviewed publication history. A structured, criterion-by-criterion rebuttal is far more persuasive than a general objection.